Abstract:19132 Background: EGFR TKI has proved to be effective as second-line or third-line drug in advanced non-small cell lung cancer (NSCLC). EGFR mutations are associated with high response of NSCLC to EGFR TKI and may be with better survival. But it is difficult to get enough tissue for detection of the mutations in advance NSCLC patients. The purpose of the study was to detect EGFR mutations from plasma or pleural effusion and correlate the mutations with the efficacy of gefitinib. Methods: Advanced NSCLC patients failing in first-line chemotherapy or intolerable to chemotherapy were enrolled. The mutations of EGFR exons 19 and 21 were detected from their plasma or pleural effusions before gefitinib treatment with the method of real-time PCR usign TaqMan-MGB probe. The patients were given oral gefitinib 250mg/d up to disease progression or intolerable toxicity. Results: 89 advanced NSCLC entered into this study, including M/F: 55 vs 45%; Stage IIIb/IV: 98/2%; Adeno/Squa/other Ca.: 77.5/12.4/10.1%; PS 0–2/2–3: 57.3/42.7%; Smokers/non-smokers: 41.6/58.4%; first-line therapy/second-line therapy:25.8/74.2% with average age of 58 yrs old. Overall response rate and disease control rate were 29.2% and 63.6% respectively. The mutation rate was 21.4% in plasma (n=59) and 31.3% in pleural effusions (n=32). The response rate and disease control rate were 91% and 100% in EGFR mutant patients and 6% and 48% in EGFR wild-type patients (p<0.01). Progression free survival and median survival were 12 months and 15 months in EGFR mutant patients and 2.7 months and 5.7 months in wild-type patients (p<0.01) respectively. Mutation rate was 76.9% in patients with partial response, 6.7% in those with stable disease and 0% in those with disease progression. Toxicity was acceptable and similar in the patients with mutant EGFR and wild-type EGFR. Conclusion Detection of EGFR mutations with PCR by TaqMan-MGB probes in pleural effusions and plasma was feasible. EGFR mutant patients were highly responsive to gefitnib and get better survival benefit than wild-type patients. No significant financial relationships to disclose.

EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma.

The inhibitory effect of CL-387785 on the invasion and metastasis of T790M EGFR mutant H1975 cells and its sensitization of radiotherapy

Abstract 2078: CK-101 (RX518), a Mutant-Selective Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC

EGFR Inhibitor Gefitinib Regulates Barrier Function in Human Epidermal Keratinocytes Via the Modulation of the Expression of Claudins

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Clinical Activity of the Mutant-Selective EGFR Inhibitor AZD9291 in Patients with EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer.

EGFR antibody radiosensitivity enhancement on CL187 cancer cells after continous low dose rate irradiation

Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

Inhibitory effect and mechanism of gefitinib combined with metformin on EGFR-TKI intrinsic resistant NSCLC H1975 cells

Knockdown of the Bcl-2 Gene Increases Sensitivity to Egfr Tyrosine Kinase Inhibitors in the H1975 Lung Cancer Cell Line Harboring T790m Mutation

Sensitization of Epidermal Growth Factor Receptor (EGFR) Inhibitors Induced by Radiotherapy Combined with Programmed Death Ligand-1 (PD-L1) Inhibitors

EGFR Inhibitors Sensitize Non-Small Cell Lung Cancer Cells to TRAIL-induced Apoptosis

Effect of EG00229 on Radiation Resistance of Lung Adenocarcinoma Cells.

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

[Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines].

Effect Of Egfr Mutations On Gefitinib In Advanced Previous Treated Non-Small-Cell Lung Cancer

Afatinib Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Cells with Acquired Egfr T790m Mutation

Preclinical Pharmacodynamic Evaluation of Drug Candidate Sklb-178 in the Treatment of Non-Small Cell Lung Cancer